Abstract
Realization of part of clinical trial called: A multicenter, Phase III, Open-label, Randomized Study in Relapsed/refractory Patients with chronic lymphocytic leukemia to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab